Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | SVP Strategy Investor Relation | June 21, 2017 | June 23, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date June 21, 2017 · Filed June 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,693 |
Ending reported balance
After 2017-06-22 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2017-06-21 · Exercise / conversion · Acquired 4,500 · Balance 9,193 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 2 · 2017-06-21 · Tax withholding · Disposed 270 · Balance 8,923 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 3 · 2017-06-21 · Tax withholding · Disposed 1,961 · Balance 6,962 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 4 · 2017-06-22 · Sale · Disposed 395 · Balance 6,567 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2: Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 5 · 2017-06-22 · Sale · Disposed 100 · Balance 6,467 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 6 · 2017-06-22 · Sale · Disposed 100 · Balance 6,367 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 7 · 2017-06-22 · Sale · Disposed 100 · Balance 6,267 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 8 · 2017-06-22 · Sale · Disposed 274 · Balance 5,993 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3: Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 9 · 2017-06-22 · Sale · Disposed 200 · Balance 5,793 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 10 · 2017-06-22 · Sale · Disposed 200 · Balance 5,593 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 11 · 2017-06-22 · Sale · Disposed 200 · Balance 5,393 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 12 · 2017-06-22 · Sale · Disposed 400 · Balance 4,993 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7: Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Row 13 · 2017-06-22 · Sale · Disposed 100 · Balance 4,893 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 14 · 2017-06-22 · Sale · Disposed 100 · Balance 4,793 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Row 15 · 2017-06-22 · Sale · Disposed 100 · Balance 4,693 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.63 · Expires 2020-12-14 | Direct | 3,000 |
Reported balance
After 2017-06-21 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2017-06-21 · Exercise / conversion · Disposed 4,500 · Balance 3,000 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8: The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | Indirectby GRAT | 11,805 |
Reported balance
Holding disclosure · report date 2017-06-21 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 11,805 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 448 |
Reported balance
Holding disclosure · report date 2017-06-21 · row 17
Holding and transaction disclosures are not merged.
1 source rowRow 17 · Balance 448 |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F3: Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F4: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F5: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F6: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F7: Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price.
F8: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $541.00 | $54,100.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 15 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $538.30 | $53,830.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 14 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,793 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $537.50 | $53,750.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 13 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,893 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 400 | $536.52 | $214,608.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 12 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,993 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $534.51 | $106,902.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 11 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,393 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $533.48 | $106,696.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 10 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,593 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $532.27 | $106,454.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 9 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,793 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 274 | $531.51 | $145,633.74 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 8 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,993 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $530.66 | $53,066.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 7 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,267 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $529.61 | $52,961.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 6 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,367 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $526.02 | $52,602.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 5 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,467 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 395 | $525.21 | $207,457.95 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 4 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,567 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · derivative · entry 18 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 4,500 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 1,961 | $510.02 | $1,000,149.22 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 3 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,962 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 270 | $510.02 | $137,705.40 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 2 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,923 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,500 | $30.63 | $137,835.00 |
DisclosureSEC source: 0001708138-17-000011 · edgardoc.xml · nonDerivative · entry 1 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 21:17 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,675 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000092 · edgardoc.xml · derivative · entry 1 Aberman Michael S · CIK 0001487767 · SVP Strategy Investor Relation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,675 Underlying: Common Stock · 21,675 shares Expires 2026-12-16 F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.